Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hepatology Reports
Erschienen in: Current Hepatology Reports 1/2024

11.01.2024

TIPS for Refractory Ascites and Hepatic Hydrothorax

verfasst von: Anjana Rajan, Justin Boike

Erschienen in: Current Hepatology Reports | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review summarizes the pathophysiology of portal hypertension, outcome data through the years supporting the use of TIPS in refractory ascites (RA) and hepatic hydrothorax (HH), and considerations for ideal TIPS candidates.

Recent Findings

Advances in stent technology over the last three decades have dramatically improved both quality of life and survival for patients with RA and HH. Importantly, the advent of controlled-expansion, covered stents has reduced the incidence of post-TIPS hepatic encephalopathy (HE) and mortality rates.

Summary

Controlled-expansion covered stents are now the guideline-recommended device for patients undergoing TIPS. Prospective trials including these newer TIPS recipients are still needed to determine ideal stent diameter, effective intra-operative portosystemic gradient cutoffs, and utility of pharmacologic HE prophylaxis for the indications of RA and/or HH.
Literatur
1.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII – renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74.PubMedCrossRef
2.
Planas R, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4(11):1385–94.PubMedCrossRef
3.
4.
Osman KT, Abdelfattah AM, Mahmood SK, Elkhabiry L, Gordon FD, Qamar AA. Refractory hepatic hydrothorax is an independent predictor of mortality when compared to refractory ascites. Dig Dis Sci. 2022;67(10):4929–38.PubMedCrossRef
5.
Boike JR, Thornburg BG, Asrani SK, Fallon MB, Fortune BE, Izzy MJ, et al. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension. Clin Gastroenterol Hepatol. 2022;20(8):1636-1662.e36.PubMedCrossRef
6.
Rössle M, Richter GM, Nöldge G, Palmaz JC, Wenz W, Gerok W. New non-operative treatment for variceal haemorrhage. Lancet. 1989;334(8655):153.CrossRef
7.
Carroll A, Boike JR. TIPS: indications, contraindications, and evaluation. Curr Gastroenterol Rep. 2023;25(10):232–41.PubMedCrossRef
8.
Martell M, Coll M, Ezkurdia N, Raurell I, Genescà J. Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol. 2010;2(6):208–20.PubMedPubMedCentralCrossRef
9.
Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(2 Suppl 1):S121–31.PubMedCrossRef
10.
McConnell M, Iwakiri Y. Biology of portal hypertension. Hepatol Int. 2018;12(Suppl 1):11–23.PubMedCrossRef
11.
Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. 2021;3(4):100316.
12.
Witte CL, Witte MH, Dumont AE. Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology. 1980;78(5 Pt 1):1059–68.PubMedCrossRef
13.
Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010;30(7):937–47.PubMedCrossRef
14.
Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014–48.PubMedCrossRef
15.
Ginés P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology. 1987;93(2):234–41.PubMedCrossRef
16.
Arora V, Vijayaraghavan R, Maiwall R, Sahney A, Thomas SS, Ali R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure. Hepatology. 2020;72(3):1043–55.PubMedCrossRef
17.
Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172–81.PubMedCrossRef
18.
Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59(7):988–1000.PubMedCrossRef
19.
Itkin M, Trerotola SO, Stavropoulos SW, Patel A, Mondschein JI, Soulen MC, et al. Portal flow and arterioportal shunting after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol. 2006;17(1):55–62.PubMedCrossRef
20.
Stankovic Z, Rössle M, Euringer W, Schultheiss M, Salem R, Barker A, et al. Effect of TIPS placement on portal and splanchnic arterial blood flow in 4-dimensional flow MRI. Eur Radiol. 2015;25(9):2634–40.PubMedCrossRef
21.
Lafortune M, Martinet JP, Denys A, Patriquin H, Dauzat M, Dufresne MP, et al. Short- and long-term hemodynamic effects of transjugular intrahepatic portosystemic shunts: a Doppler/manometric correlative study. AJR Am J Roentgenol. 1995;164(4):997–1002.PubMedCrossRef
22.
Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study. Hepatology. 1994;19(1):129–32.PubMedCrossRef
23.
Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology. 1999;29(3):632–9.PubMedCrossRef
24.
Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med. 1995;122(11):816–22.PubMedCrossRef
25.
Riggio O, Merli M, Pedretti G, Servi R, Meddi P, Lionetti R, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci. 1996;41(3):578–84.PubMedCrossRef
26.
Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73(6):1526–47.PubMedCrossRef
27.
Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol. 1996;25(2):135–44.PubMedCrossRef
28.
Rössle M, Ochs A, Gülberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 2000;342(23):1701–7.PubMedCrossRef
29.
Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123(6):1839–47.PubMedCrossRef
30.
Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American study for the treatment of refractory ascites. Gastroenterology. 2003;124(3):634–41.PubMedCrossRef
31.
Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40(3):629–35.PubMedCrossRef
32.
Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H, et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol. 2011;46(1):78–85.PubMedCrossRef
33.
D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology. 2005;129(4):1282–93.PubMedCrossRef
34.
Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database of Systematic Reviews. 2006 Oct 18;2010(1). 2006;2006(4):CD004889.
35.
Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133(3):825–34.PubMedCrossRef
36.
Deltenre P, Mathurin P, Dharancy S, Moreau R, Bulois P, Henrion J, et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int. 2005;25(2):349–56.PubMedCrossRef
37.
Nazarian GK, Bjarnason H, Dietz CA, Bernadas CA, Foshager MC, Ferral H, et al. Refractory ascites: midterm results of treatment with a transjugular intrahepatic portosystemic shunt. Radiology. 1997;205(1):173–80.PubMedCrossRef
38.
Casado M, Bosch J, García-Pagán JC, Bru C, Bañares R, Bandi JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology. 1998;114(6):1296–303.PubMedCrossRef
39.
Hernández-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology. 2004;40(5):1197–202.PubMedCrossRef
40.
Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology. 2010;51(1):306–306.PubMedCrossRef
41.
Perarnau JM, Le Gouge A, Nicolas C, D’Alteroche L, Borentain P, Saliba F, et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial. J Hepatol. 2014;60(5):962–8.PubMedCrossRef
42.
Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: results of a randomized study. Gastroenterology. 2004;126(2):469–75.PubMedCrossRef
43.
Bureau C, Pagan JCG, Layrargues GP, Metivier S, Bellot P, Perreault P, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int. 2007;27(6):742–7.PubMedCrossRef
44.
Huang Q, Wu X, Fan X, Cao J, Han J, Xu L, et al. Comparison study of Doppler ultrasound surveillance of expanded polytetrafluoroethylene-covered stent versus bare stent in transjugular intrahepatic portosystemic shunt. J Clin Ultrasound. 2010;38(7):353–60.PubMedCrossRefADS
45.
Wang L, Xiao Z, Yue Z, Zhao H, Fan Z, Zhao M, et al. Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: a single-center randomized trial OPEN. Nature Publishing Group. 2016;6.
46.
Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157–63.PubMedCrossRef
47.
Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol. 2014;20(10):2704–14.PubMedPubMedCentralCrossRef
48.
Sommer CM, Gockner TL, Stampfl U, Bellemann N, Sauer P, Ganten T, et al. Technical and clinical outcome of transjugular intrahepatic portosystemic stent shunt: bare metal stents (BMS) versus viatorr stent-grafts (VSG). Eur J Radiol. 2012;81(9):2273–80.PubMedCrossRef
49.
Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103(11):2738–46.PubMedCrossRef
50.
Taylor AG, Kolli KP, Kerlan RK. Techniques for transjugular intrahepatic portosystemic shunt reduction and occlusion clinical evaluation of the patient. Tech Vasc Interv Radiol. 2016;19(1):74–81.PubMedCrossRef
51.
Rowley MW, Choi M, Chen S, Hirsch K, Anil SB. Refractory hepatic encephalopathy after elective transjugular intrahepatic portosystemic shunt: risk factors and outcomes with revision. Cardiovasc Intervent Radiol. 2018;41(11):1765–72.PubMedCrossRef
52.
Miraglia R, Maruzzelli L, Tuzzolino F, Petridis I, D’Amico M, Luca A. Transjugular intrahepatic portosystemic shunts in patients with cirrhosis with refractory ascites: comparison of clinical outcomes by using 8- and 10-mm PTFE-covered stents. Radiology. 2017;284(1):281–8.PubMedCrossRef
53.
Riggio O, Ridola L, Angeloni S, Cerini F, Pasquale C, Attili AF, et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial. J Hepatol. 2010;53(2):267–72.PubMedCrossRef
54.
Wang Q, Lv Y, Bai M, Wang Z, Liu H, He C, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol. 2017;67(3):508–16.PubMedCrossRef
55.
Trebicka J, Bastgen D, Byrtus J, Praktiknjo M, Terstiegen S, Meyer C, et al. Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival. Clin Gastroenterol Hepatol. 2019;17(13):2793-2799.e1.PubMedCrossRef
56.
Borghol S, Perarnau JM, Pucheux J, D’Alteroche L, Ayoub J, Trillaud H. Short- and long-term evolution of the endoluminal diameter of underdilated stents in transjugular intrahepatic portosystemic shunt. Diagn Interv Imaging. 2016;97(11):1103–7.PubMedCrossRef
57.
Gaba RC, Parvinian A, Minocha J, Casadaban LC, Knuttinen MG, Ray CE, et al. Should transjugular intrahepatic portosystemic shunt stent grafts be underdilated? J Vasc Interv Radiol. 2015;26(3):382–7.PubMedCrossRef
58.
Pieper CC, Jansen C, Meyer C, Nadal J, Lehmann J, Schild HH, et al. Prospective evaluation of passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stent grafts—a three-dimensional sonography study. J Vasc Interv Radiol. 2017;28(1):117–25.PubMedCrossRef
59.
Schepis F, Vizzutti F, Garcia-Tsao G, Marzocchi G, Rega L, De Maria N, et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis. Clin Gastroenterol Hepatol. 2018;16(7):1153-1162.e7.PubMedCrossRef
60.
• Dell T, Menne M, Wagenpfeil J, Praktiknjo M, Jansen C, Isaak A, et al. How controlled is the expansion of VIATORR CX? Cardiovasc Intervent Radiol. 2023;46(5):658–63. Dell et al. verify that new controlled-expansion covered stents do not passively expand over time and maintain the desired diameter.PubMedPubMedCentralCrossRef
61.
• Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, et al. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep. 2021;3(3):100264. In this prospective case-control study of 114 patients, underdilation of controlled expansion stents confers improved survival and ascites control as well as decreased incidence of HE and heart failure when compared to older covered stents.PubMedPubMedCentralCrossRef
62.
• Queck A, Schwierz L, Gu W, Ferstl PG, Jansen C, Uschner FE, et al. Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS. Hepatology. 2023;77(2):466–75. In this retrospective single-center trial, Queck et al. propose a target portal pressure gradient (PPG) of <10mm or PPG reduction > 60% in patients undergoing TIPS for refractory ascites. Currently, a PPG goal is validated only for the indication of variceal bleeding.PubMedCrossRef
63.
Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of The International Ascites Club. Hepatology. 2003;38(1):258–66.PubMedCrossRef
64.
Arroyo V, Ginés P, Ginés G, Gerbes AL, Dudley FJ, Gentilini P, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23(1):164–76.PubMedCrossRef
65.
Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60.CrossRef
66.
Piecha F, Radunski UK, Ozga AK, Steins D, Drolz A, Horvatits T, et al. Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival. JHEP Rep. 2019;1(2):90–8.PubMedPubMedCentralCrossRef
67.
Bureau C, Métivier S, D’Amico M, Péron JM, Otal P, Pagan JCG, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol. 2011;54(5):901–7.PubMedCrossRef
68.
Salerno F, Merli M, Cazzaniga M, Valeriano V, Rossi P, Lovaria A, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36(4):494–500.PubMedCrossRef
69.
Krishnan A, Woreta TA, Vaidya D, Liu Y, Hamilton JP, Hong K, et al. MELD or MELD-Na as a predictive model for mortality following transjugular intrahepatic portosystemic shunt placement. J Clin Transl Hepatol. 2023;11(1):38–44.PubMed
70.
Montgomery A, Ferral H, Vasan R, Postoak DW. MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures. Cardiovasc Intervent Radiol. 2005;28(3):307–12.PubMedCrossRef
71.
Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011;26(6):943–51.PubMedCrossRef
72.
Nardelli S, Gioia S, Pasquale C, Pentassuglio I, Farcomeni A, Merli M, et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2016;111(4):523–8.PubMedCrossRef
73.
• Saab S, Zhao M, Asokan I, Yum JJ, Lee EW. History of hepatic encephalopathy is not a contraindication to transjugular intrahepatic portosystemic shunt placement for refractory ascites. Clin Transl Gastroenterol. 2021;12(8):e00378. Saab et al. reveal in this retrospective single-center study that a history of medically-controlled HE does not worsen post-TIPS survival or HE incidence in patients undergoing TIPS for RA. Therefore, they suggest a history of HE is not a contraindication to TIPS if not clinically significant.PubMedPubMedCentralCrossRef
74.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35.PubMedCrossRef
75.
Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42(5):674–9.PubMedCrossRef
76.
Bureau C, Thabut D, Jezequel C, Archambeaud I, D'Alteroche L, Dharancy S, et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt:a randomized controlled trial. Ann Intern Med. 2021;174(5):633–40.PubMedCrossRef
77.
Coronado WM, Ju C, Bullen J, Kapoor B. Predictors of occurrence and risk of hepatic encephalopathy after TIPS creation: a 15-year experience. Cardiovasc Intervent Radiol. 2020;43(8):1156–64.PubMedCrossRef
78.
Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol. 2017;15(6):934–6.PubMedCrossRef
79.
Wannhoff A, Hippchen T, Weiss CS, Friedrich K, Rupp C, Neumann-Haefelin C, et al. Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt. Aliment Pharmacol Ther. 2016;43(9):955–65.PubMedCrossRef
80.
Billey C, Billet S, Robic MA, Cognet T, Guillaume M, Vinel JP, et al. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the Toulouse algorithm. Hepatology. 2019;70(6):1928–41.PubMedCrossRef
81.
Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104(10):2458–66.PubMedCrossRef
82.
Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut. 2007;56(6):869–75.PubMedPubMedCentralCrossRef
83.
Ditah IC. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: a systematic review and cumulative meta-analysis. World J Hepatol. 2015;7(13):1797–806.PubMedPubMedCentralCrossRef
84.
Alberts WM, Salem AJ, Solomon DA, Boyce G. Hepatic hydrothorax. Cause and management. Arch Intern Med. 1991;151(12):2383–8.PubMedCrossRef
85.
86.
Rubinstein D, McInnes IE, Dudley FJ. Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management. Gastroenterology. 1985;88(1):188–91.PubMedCrossRef
87.
88.
Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology. 2014;59(4):1627–37.PubMedCrossRef
89.
Cardenas A, Kelleher T, Chopra S. Hepatic hydrothorax. Aliment Pharmacol Ther. 2004;20(3):271–9.PubMedCrossRef
90.
Liu LU, Haddadin HA, Bodian CA, Sigal SH, Korman JD, Bodenheimer HC, et al. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest. 2004;126(1):142–8.PubMedCrossRef
91.
Runyon BA, Greenblatt M, Ming RH. Hepatic hydrothorax is a relative contraindication to chest tube insertion. Am J Gastroenterol. 1986;81(7):566–7.PubMed
92.
Ridha A, Al-Abboodi Y, Fasullo M. The outcome of thoracentesis versus chest tube placement for hepatic hydrothorax in patients with cirrhosis: a nationwide analysis of the national inpatient sample. Gastroenterol Res Pract. 2017;2017:1–4.CrossRef
93.
Gordon FD, Anastopoulos HT, Crenshaw W, Gilchrist B, McEniff N, Falchuk KR, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology. 1997;25(6):1366–9.PubMedCrossRef
94.
Jeffries MA, Kazanjian S, Wilson M, Punch J, Fontana RJ. Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl Surg. 1998;4(5):416–23.PubMedCrossRef
95.
Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rössle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol. 2001;13(5):529–34.PubMedCrossRef
96.
Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol. 2002;13(4):385–90.PubMedCrossRef
97.
Wilputte JY, Goffette P, Zech F, Godoy-Gepert A, Geubel A. The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients. Acta Gastroenterol Belg. 2007;70(1):6–10.PubMed
98.
Dhanasekaran R, West JK, Gonzales PC, Subramanian R, Parekh S, Spivey JR, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol. 2010;105(3):635–41.PubMedCrossRef
99.
Young S, Bermudez J, Zhang L, Rostambeigi N, Golzarian J. Transjugular intrahepatic portosystemic shunt (TIPS) placement: a comparison of outcomes between patients with hepatic hydrothorax and patients with refractory ascites. Diagn Interv Imaging. 2019;100(5):303–8.PubMedCrossRef
100.
Gou X, Jia W, He C, Yuan X, Niu J, Xu J, et al. Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients. Eur Radiol. 2023;33(5):3407–15.PubMedCrossRef
Metadaten
Titel
TIPS for Refractory Ascites and Hepatic Hydrothorax
verfasst von
Anjana Rajan
Justin Boike
Publikationsdatum
11.01.2024
Verlag
Springer US
Erschienen in
Current Hepatology Reports / Ausgabe 1/2024
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-023-00625-4

Weitere Artikel der Ausgabe 1/2024

Current Hepatology Reports 1/2024 Zur Ausgabe

ReviewPaper

Indication of Liver Transplant for HCC: Current Status and Future Directions

ReviewPaper

Prophylaxis and Treatment of Bacterial Infections in Cirrhosis

ReviewPaper

Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon

ReviewPaper

Hepatic Sarcoidosis: A Review of the Diagnosis and Management

ReviewPaper

Precision Management of Patients with HBV Infection

ReviewPaper

Cholestatic Pruritus: Pathophysiology, Current Management Approach, and Emerging Therapies

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise